Posted by Michael Wonder on 11 Jan 2023
Nivolumab in combination with platinum and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with advanced, HER2 negative gastric, gastro-oesophageal junction or oesophageal adenocarcinoma
11 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of nivolumab in the NHS in England.
Nivolumab, when used in combination with platinum and fluoropyrimidine-based chemotherapy, is recommended as an option for the first-line treatment of adults with advanced or metastatic, HER2 negative gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD‑L1 with a combined positive score of 5 or more.
